{"id":888671,"date":"2025-09-23T08:17:51","date_gmt":"2025-09-23T12:17:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/"},"modified":"2025-09-23T08:17:51","modified_gmt":"2025-09-23T12:17:51","slug":"mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/","title":{"rendered":"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland"},"content":{"rendered":"<h2>\nCompany Provides Update on eAArly DETECT 2 Study<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BERKELEY, Calif. and MAINZ, Germany, Sept.  23, 2025  (GLOBE NEWSWIRE) &#8212; Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship product, ColoAlert\u00ae, in Switzerland.<\/p>\n<p>This milestone comes as the result of several key achievements. Earlier this year, Mainz Biomed signed a strategic partnership with\u00a0labor team w ag (\u201clabor team\u201d), one of the country\u2019s leading diagnostic laboratories. This collaboration provides a strong foundation for ColoAlert\u2019s successful introduction, ensuring that patients and physicians across Switzerland will have access to the test through an established and trusted network.<\/p>\n<p>Following this, Swissmedic, the Swiss authority responsible for therapeutic product regulation, granted official registration and marketing approval for ColoAlert\u00ae. This authorization enables the test to be distributed in Switzerland and marks an important regulatory step toward expanding patient access to innovative colorectal cancer screening solutions.<\/p>\n<p>In addition, Mainz Biomed successfully completed a comprehensive technology transfer with labor team, enabling the laboratory to process and analyze ColoAlert\u00ae samples directly at its state-of-the-art facility in Goldach, Switzerland. This local implementation not only ensures operational efficiency but also guarantees that Swiss patients benefit from high-quality diagnostics performed within their own healthcare system.<\/p>\n<p>Together, these accomplishments have paved the way for the commercial launch of ColoAlert\u00ae, making the test available to patients and healthcare providers throughout Switzerland.<\/p>\n<p>The Company continues to make progress on recruitment for its 2,000 patient, average risk population study. With its goal of completing enrollment by the end of 2025, management has decided not to pause the study for an interim readout, but instead completing enrollment, analysis, and read out on the completed study.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jirFFB5TbAIPYHBO0c7IihtAxHleH4BIr6KoPHR7hKVW5o3frnBJARIwUQE7_DuD99n1502lulAFgnzv2-3EeRVfGNFK24Fa52W-pKdKFZBcqRAst5lLDmhGgOe5SlH32SSF4W7Rv_BNizVibJDuys9I37qGfKcSnIQwueesj7hEAOp76kKXwTyWmwP4KAao4Zzbmhz-voK_E1QsthxXSfYrB4ty5gPnhiWuCBOB8D8=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Please visit Mainz Biomed\u2019s official website for investors at mainzbiomed.com\/investors\/ for more information <\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>Please follow us to stay up to date:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FJeC04blnygXJZTGeSD7BG5PAgZ5KnMIOSgpYcjcUkHTV4vd-wyFV4pTWnYiL0DeRcf-tG5Avs-OJRZNprzCd-KXBVcY-kh2hAn9H6Ftbm0ol8Y3MNd5AQbil5DYBXhp\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jk46DOj01mptjUaRfrnUsTe9TzYgmE5MpQt8VVE6EvKSLO68Z9GMhhUgExfs_YVk6SDRC5rM88JNUskSl_mxzZd3NJZuC8iUnCgr942uXtZFPWVTQsAZY69XhajBQpEq\" rel=\"nofollow\" target=\"_blank\"><strong>X (Previously Twitter)<\/strong><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DWpnv_DrpF2LQFr1CyLeB-h3Sn1z8fWhEBRWI27JcyAruSJ9yzZPjMIzcJuX1LiYsL2DzOPuzcEb2msK1KFDIxjYYy6qV-fQfD-OGbi0hBw=\" rel=\"nofollow\" target=\"_blank\"><strong>Facebook<\/strong><\/a><\/p>\n<p>\n        <strong>About Mainz Biomed NV<\/strong><br \/>\n        <br \/>Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company\u2019s flagship product is ColoAlert\u00ae, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert\u00ae is marketed across Europe. The Company is currently running its eAArly DETECT clinical study in preparation for it pivotal FDA study for US regulatory approval. Mainz Biomed\u2019s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ARW-0Y13U7vzv-NwjZ2HWHaKUjixFt8lndFfNYoKf2KIiaDiSAXrDnfGPqdXSuwhzHn8Hdw7k6CNG1lRGRwWU7ATc8RV5XsRwhTLKCohvec=\" rel=\"nofollow\" target=\"_blank\"><strong>mainzbiomed.com<\/strong><\/a><strong> or follow us on <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FJeC04blnygXJZTGeSD7BC_buhrf8flbFhQuhadghhor6hGm-TggKXH18R5ll-pa_qvu256Tn5FWL5CH2Owy9yu9nBIDXbJ-CqhVpqGu5mn8FJbAaSOSunOUqu-EcNTe\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a><strong>, <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wRLg9HUXdi1t05vkq0YA3SZHUuQ_LTk0WIEwaslvmX-yw_VoFlS8ZqpxODv5zEHTqYkzh0esEzpHEqfn_qZsg5KDX01614x2POoBpSBpmdg=\" rel=\"nofollow\" target=\"_blank\"><strong>Twitter<\/strong><\/a><strong> and <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DWpnv_DrpF2LQFr1CyLeB31Xronmi4v5JRsE88IOPvPHq2Qx3fFoe17vMkxkG_nNgHU3npdVm4L7fH2n21tmcp3WFk-R8Ju1GiJavvKEMLw=\" rel=\"nofollow\" target=\"_blank\"><strong>Facebook<\/strong><\/a><strong>.<\/strong><\/p>\n<p>\n        <strong>For media inquiries<\/strong><br \/>\n        <br \/>MC Services AG<br \/>Maximilian Schur \/ Simone Neeten<br \/>+49 211 529252 20<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ARW-0Y13U7vzv-NwjZ2HWPkVXkH-PjZlRtx_88jfYezbrWiYFM4Nbcxny4XbfT77qO9_9fvBRhwrVGrrDz1hnRwrCgLCT_1NPj-aK5LVTB7EQhEKJ4d_Fp9zthLA54Os\" rel=\"nofollow\" target=\"_blank\"><strong>mainzbiomed@mc-services.eu<\/strong><\/a><\/p>\n<p><strong>For investor inquiries, please contact <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gNIzAq-uJbgR_YtnpKYh0ApGS7a84C2qM89gqmMkYOvr6-SUJumK3OtS_EkvEHOLV089l6-_B88Dx87UYacFcD1JD_r12W75YN40n1uo1EM=\" rel=\"nofollow\" target=\"_blank\"><strong>ir@mainzbiomed.com<\/strong><\/a><\/p>\n<p><strong>Forward-Looking Statements<\/strong><br \/>Certain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201coutlook\u201d, and \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company\u2019s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the \u201cSEC\u201d) by the Company. Additional information concerning these and other factors that may impact the Company\u2019s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company\u2019s SEC filings are available publicly on the SEC\u2019s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NzAyNjcxNGYtNWJlMy00YWVmLTlhYjgtNmZiOTlkNDY1ZDBlLTEyMzU2NDItMjAyNS0wOS0yMy1lbg==\/tiny\/Mainz-BioMed-NV.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company Provides Update on eAArly DETECT 2 Study BERKELEY, Calif. and MAINZ, Germany, Sept. 23, 2025 (GLOBE NEWSWIRE) &#8212; Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship product, ColoAlert\u00ae, in Switzerland. This milestone comes as the result of several key achievements. Earlier this year, Mainz Biomed signed a strategic partnership with\u00a0labor team w ag (\u201clabor team\u201d), one of the country\u2019s leading diagnostic laboratories. This collaboration provides a strong foundation for ColoAlert\u2019s successful introduction, ensuring that patients and physicians across Switzerland will have access to the test through an established and trusted network. Following this, Swissmedic, the Swiss &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-888671","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company Provides Update on eAArly DETECT 2 Study BERKELEY, Calif. and MAINZ, Germany, Sept. 23, 2025 (GLOBE NEWSWIRE) &#8212; Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship product, ColoAlert\u00ae, in Switzerland. This milestone comes as the result of several key achievements. Earlier this year, Mainz Biomed signed a strategic partnership with\u00a0labor team w ag (\u201clabor team\u201d), one of the country\u2019s leading diagnostic laboratories. This collaboration provides a strong foundation for ColoAlert\u2019s successful introduction, ensuring that patients and physicians across Switzerland will have access to the test through an established and trusted network. Following this, Swissmedic, the Swiss &hellip; Continue reading &quot;Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T12:17:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland\",\"datePublished\":\"2025-09-23T12:17:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/\"},\"wordCount\":782,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/\",\"name\":\"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==\",\"datePublished\":\"2025-09-23T12:17:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/","og_locale":"en_US","og_type":"article","og_title":"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland - Market Newsdesk","og_description":"Company Provides Update on eAArly DETECT 2 Study BERKELEY, Calif. and MAINZ, Germany, Sept. 23, 2025 (GLOBE NEWSWIRE) &#8212; Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship product, ColoAlert\u00ae, in Switzerland. This milestone comes as the result of several key achievements. Earlier this year, Mainz Biomed signed a strategic partnership with\u00a0labor team w ag (\u201clabor team\u201d), one of the country\u2019s leading diagnostic laboratories. This collaboration provides a strong foundation for ColoAlert\u2019s successful introduction, ensuring that patients and physicians across Switzerland will have access to the test through an established and trusted network. Following this, Swissmedic, the Swiss &hellip; Continue reading \"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-23T12:17:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland","datePublished":"2025-09-23T12:17:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/"},"wordCount":782,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/","name":"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==","datePublished":"2025-09-23T12:17:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyOTI5OCM0MDIyMjcxNTYjMjIyNDA4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mainz Biomed Announces Commercial Launch of ColoAlert\u00ae in Switzerland"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=888671"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888671\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=888671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=888671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=888671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}